Presentation 9

Blood-Derived Progenitor Cells - A Potentially Powerful Theraputic Tool
Dr. Valentin Fulga, Dr.Valentin Fulga, Dr.David Czeiger, Dr.yael Porat
Thera Vitae and Soroka Medical Center

***********************************

TheraVitae, one of the World Economic Forum Technology Pioneers for 2006, is a leading biotechnology company with the mission of developing and mass producing cell therapies for incurable diseases using blood-derived adult stem cells. An international company, TheraVitae has successfully treated more than 80 patients suffering from end stage heart disorders who had no other therapeutic option. TheraVitae’s technology is based on the isolation of a novel blood-derived cell population, termed synergetic cell population (SCP) that is rich in multipotent progenitor cells and capable of differentiating into a variety of cell lineages.

VesCell(TM), the company’s lead product, utilizes progenitor cells originating from the same individual to whom they are later administered (autologous). It consists of Angiogenic Cell Precursors (ACPs), which promote blood vessel and heart tissue generation and repair. The product is manufactured under strict GMP-compliant conditions and has been proven safe and effective in a clinical trial in Thailand. The company is initiating soon additional clinical trials in Hong Kong and Taiwan to test the safety and efficacy of the product in additional indications, such as peripheral arterial disease. The simple and rapid method of SCP isolation from peripheral blood and the robust plasticity demonstrated by its components make the SCP a powerful and broad platform for the development of a variety of autologous treatments for diseases hitherto considered incurable.

**********************************

http://www.theravitae.com/
http://web.israelinsider.com/Articles/Diplomacy/7444.htm
VesCell(TM) http://www.vescell.com/
http://www.brainstorm-cell.com/
http://www.weforum.org/